The latest announcements and milestones from SentinusAI® and Ainnocence
Research on AI-designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains has been published in Nature Scientific Reports, demonstrating the platform's ability to predict variant escape and achieve significant affinity improvements.
Publication Peer-ReviewedC&EN highlighted how sequence-based AI bypasses the limitations of structural snapshots, leverages vastly more abundant experimental data, and unlocks scalable discovery across chemical and biological space—marking a turning point similar to the inflection moments seen in large language models and protein foundation models.
Press Coverage BioSpaceThe upgraded model is now being rolled into SentinusAI® (antibody engineering), CarbonAI® (small-molecule & PROTAC design) and CellulaAI® (cell-therapy optimization). Higher-fidelity predictions of stability and expression accelerate antibody lead-opt studies, while enhanced activity/binding scores improve small-molecule hit selection.
Technology Platform UpdateAinnocence unveils a powerful animal-free platform set to revolutionize the field of antibody discovery and optimization by replacing traditional antibody screening methods such as phage display, hybridoma technology and B-cell selection.
Product Launch Yahoo FinanceAinnocence debuts two services that automatically generate highly optimized drug-like molecules within just hours to solve some of the most complex drug discovery challenges: SentinusAI™ for de novo antibody and fusion protein engineering.
Platform Launch PR Newswire